Flash-Player installieren
ScheBo-MediaBox



» Flash-Player installieren
ScheBo® Biotech AG
Netanyastrasse 3
35394 Giessen, Germany


Phone +49 -(0)641 -4996-0
Fax +49 -(0)641 -4996-77
Email-contact

ScheBo® Tumor M2-PK™ EDTA Plasma Test

Tumor M2-PK detects a metabolic state highly specific for a variety of tumors. Its superior usefulness was demonstrated in diagnosis and monitoring of different cancer types. It′s the first reliable tumor marker for renal cell carcinoma.


The majority of human tumors strongly overexpress an isoform of the glycolytic enzyme pyruvate kinase, the type tumor M2. This isoenzyme is released from tumor cells and is quantitatively detectable in body fluids. The concentration of the type tumor M2 isoenzyme indicates a metabolic switch turning normal cells into tumor cells. It highly correlates with the malignancy of cancer (staging) and it is independent from the histological grading.

This novel type of marker for malignancies is called Tumor M2-PK and is the only tumor metabolic marker so far. ScheBo® Biotech AG developed a highly sensitive enzyme-linked immunosorbent assay (ELISA) which allows the quantitative measurement of Tumor M2-PK in EDTA plasma. The test is based on two monoclonal antibodies which specifically react with Tumor M2-PK and do not cross react with the other isoforms of pyruvate kinase (Typ L, R, M1 and M2). As Tumor M2-PK is a highly tumor specific protein and shows no organ specificity it may be the marker of choice for a variety of tumors.

Tumor M2-PK gives additional information that is generally not provided by classical tumor markers which reflect tumor burden.

First reliable tumor marker for renal cell carcinoma:

Urological centers have shown the suitability of Tumor M2-PK as a marker for renal cell carcinoma. Since Tumor M2-PK is a highly tumor specific protein and has not shown any organ specificity, the test is also suitable for the diagnosis of non-urogenital tumors.


The following tumors are detected with the ScheBo® Tumor M2-PK™ EDTA Plasma Test:

  • Renal cell carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Oesophageal carcinoma
  • Lung cancer
  • Breast cancer
  • Pancreatic cancer




A Decade of UK Success for Schebo Biotech
ScheBo® Biotech UK Limited, a leading provider of unique in-vitro diagnostic tests for the healthcare sector, has just celebrated its 10th Anniversary.
more...
A superior alternative for PLT users: Faecal Pancreatic Elastase Test
Pfizer recommends this test in a letter it sent to pharmacists notifying them about the withdrawal of PLT.
more...
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
more...
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.
more...
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK
Fecal tumor M2-PK is an appropriately sensitve tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer.
more...
ISO-Certificate
Our ISO-Cerficate as pdf-download.
more...